TG Therapeutics Inc (TGTX)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 41.40% | 32.43% | 52.36% | 47.95% | 39.75% | 34.95% | -406.74% | -1,125.24% | -2,418.35% | -1,492.42% | -1,346.11% | -1,442.51% | -1,417.72% | -2,462.73% | -4,593.91% | -10,233.85% | -70,853.95% | -44,799.34% | -23,758.55% | -16,049.34% |
| Operating profit margin | 12.74% | -0.19% | 29.90% | 17.25% | 9.28% | -10.47% | -893.73% | -2,573.97% | -6,926.65% | -4,651.20% | -4,078.26% | -4,075.32% | -5,154.27% | -7,685.07% | -14,051.28% | -34,459.87% | -179,996.05% | -147,876.97% | -131,521.05% | -121,454.61% |
| Pretax margin | 7.78% | -5.29% | 28.12% | 14.85% | 5.87% | -14.32% | -930.62% | -2,662.36% | -7,124.10% | -4,749.83% | -4,144.49% | -4,126.45% | -5,204.07% | -7,784.36% | -14,271.13% | -35,158.99% | -183,802.63% | -151,798.68% | -135,198.03% | -124,230.26% |
| Net profit margin | 7.11% | -5.47% | 28.09% | 14.70% | 5.70% | -14.32% | -930.62% | -2,662.36% | -7,124.10% | -4,749.83% | -4,144.49% | -4,126.45% | -5,204.07% | -7,784.38% | -14,271.17% | -35,159.10% | -183,803.29% | -151,798.68% | -135,198.03% | -124,230.26% |
The analysis of TG Therapeutics Inc profitability ratios reveals a fluctuating performance over the years.
The Gross profit margin shows a consistent improvement from negative figures in 2020 and early 2021 to positive percentages from September 2023 onwards, indicating a better ability to cover the cost of goods sold.
The Operating profit margin also displays a similar trend, with significant negative margins in 2020 and early 2021 turning positive from December 2023 onwards, suggesting a more efficient management of operating expenses.
The Pretax margin mirrors the Operating profit margin trend, starting from highly negative values and gradually improving to positive percentages by March 2024, indicating better control over non-operating expenses.
The Net profit margin reflects the improvement seen in the other profitability ratios, showing a shift from deep negative values initially to positive figures by December 2023, which continue to improve through 2024. This suggests a positive impact on the company's bottom line and overall profitability.
Overall, the trend in profitability ratios for TG Therapeutics Inc showcases a positive trajectory in recent years, indicating enhanced operational efficiency and financial performance.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 7.26% | -0.09% | 25.38% | 12.95% | 6.26% | -5.72% | -76.38% | -82.57% | -99.62% | -107.27% | -112.80% | -106.41% | -90.82% | -82.65% | -70.46% | -56.96% | -43.73% | -82.08% | -67.85% | -181.26% |
| Return on assets (ROA) | 4.05% | -2.45% | 23.85% | 11.04% | 3.84% | -7.83% | -79.53% | -85.41% | -102.46% | -109.54% | -114.64% | -107.74% | -91.69% | -83.72% | -71.56% | -58.12% | -44.66% | -84.25% | -69.75% | -185.40% |
| Return on total capital | 9.17% | 0.09% | 36.67% | 18.83% | 7.92% | -7.18% | -122.10% | -131.49% | -148.65% | -136.19% | -143.39% | -135.69% | -113.43% | -108.70% | -88.53% | -70.19% | -51.91% | -121.02% | -92.36% | -662.92% |
| Return on equity (ROE) | 10.52% | -7.48% | 53.89% | 25.73% | 7.90% | -15.72% | -434.22% | -614.42% | -338.53% | -237.54% | -223.58% | -191.61% | -146.78% | -110.10% | -89.92% | -71.62% | -53.79% | -135.20% | -105.80% | — |
Based on the provided data for TG Therapeutics Inc, the profitability ratios exhibit significant fluctuations over the quarters analyzed.
1. Operating Return on Assets (Operating ROA):
- The Operating ROA was negative throughout the initial period, implying that the company's operating income was insufficient to cover its assets.
- However, there was a notable improvement starting from the fourth quarter of 2023, with a positive Operating ROA reaching 12.95% by March 31, 2024.
2. Return on Assets (ROA):
- Similar to Operating ROA, ROA was also negative in the early quarters, indicating poor asset utilization.
- The trend improved gradually, and by the second quarter of 2024, the ROA became positive at 23.85%.
3. Return on Total Capital:
- Return on Total Capital followed a similar negative trajectory initially, showing that the overall capital investment was not yielding adequate returns.
- The trend reversed, with positive returns achieved from the first quarter of 2024 onwards, peaking at 36.67% by June 30, 2024.
4. Return on Equity (ROE):
- The Return on Equity was negative for most quarters, indicating that shareholder value was not being effectively generated.
- Improvements were observed in the latter quarters, with positive ROE values recorded from the first quarter of 2024 to December 31, 2024, showing a turnaround in shareholder profitability.
Overall, the analysis reveals a challenging profitability performance in the initial periods, gradually transitioning to positive returns in the latter quarters. The company's enhanced profitability ratios in the recent periods suggest improved operational efficiency and financial management, which may be favorable indicators for investors and stakeholders.